Molecular characterization, reactivation, and depletion of latent HIV

被引:166
作者
Brooks, DG
Hamer, DH
Arlen, PA
Gao, LY
Bristol, G
Kitchen, CMR
Berger, EA
Zack, JA [1 ]
机构
[1] Univ Calif Los Angeles, David Geffen Sch Med, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA
[2] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA
[3] Univ Calif Los Angeles, David Geffen Sch Med, AIDS Inst, Los Angeles, CA 90095 USA
[4] Univ Calif Los Angeles, Sch Publ Hlth, Dept Biostat, Los Angeles, CA 90095 USA
[5] NCI, Biochem Lab, NIH, Bethesda, MD 20892 USA
[6] NIAID, Viral Dis Lab, NIH, Bethesda, MD 20892 USA
关键词
D O I
10.1016/S1074-7613(03)00236-X
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Antiretroviral therapy is unable to eliminate HIV infection in a small, long-lived population of latently infected T cells, providing a source for renewed viral replication following cessation of therapy. Analysis of individual latently infected cells generated in the SCID-hu (Thy/Liv) mouse demonstrated no functional viral RNA produced in the latent state. Following reactivation viral expression was dramatically increased, rendering the infected cells susceptible to an anti-HIV immunotoxin. Treatment with the immunotoxin in conjunction with agents that activate virus expression without inducing cell division (IL-7 or the non-tumor-promoting phorbol ester prostratin) depleted the bulk of the latent reservoir and left uninfected cells able to respond to subsequent costimulation. We demonstrate that activation of latent virus is required for targeting by antiviral agents and provide the basis for future therapeutic strategies to eradicate the latent reservoir.
引用
收藏
页码:413 / 423
页数:11
相关论文
共 51 条
[31]   Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART [J].
Kulkosky, J ;
Culnan, DM ;
Roman, J ;
Dornadula, G ;
Schnell, M ;
Boyd, MR ;
Pomerantz, RJ .
BLOOD, 2001, 98 (10) :3006-3015
[32]   Intensification and stimulation therapy for human immunodeficiency virus type 1 reservoirs in infected persons receiving virally suppressive highly active antiretroviral therapy [J].
Kulkosky, J ;
Nunnari, G ;
Otero, M ;
Calarota, S ;
Dornadula, G ;
Zhang, H ;
Malin, A ;
Sullivan, J ;
Xu, Y ;
DeSimone, J ;
Babinchak, T ;
Stern, J ;
Cavert, W ;
Haase, A ;
Pomerantz, RJ .
JOURNAL OF INFECTIOUS DISEASES, 2002, 186 (10) :1403-1411
[33]   HIV-1 TAT PROTEIN PROMOTES FORMATION OF MORE-PROCESSIVE ELONGATION COMPLEXES [J].
MARCINIAK, RA ;
SHARP, PA .
EMBO JOURNAL, 1991, 10 (13) :4189-4196
[34]   THE SCID-HU MOUSE - MURINE MODEL FOR THE ANALYSIS OF HUMAN HEMATOLYMPHOID DIFFERENTIATION AND FUNCTION [J].
MCCUNE, JM ;
NAMIKAWA, R ;
KANESHIMA, H ;
SHULTZ, LD ;
LIEBERMAN, M ;
WEISSMAN, IL .
SCIENCE, 1988, 241 (4873) :1632-1639
[35]  
MCCUNE JM, 1992, BONE MARROW TRANSPL, V9, P74
[37]   Increased affinity and stability of an anti-HIV-1 envelope immunotoxin by structure-based mutagenesis [J].
McHugh, L ;
Hu, S ;
Lee, BK ;
Santora, K ;
Kennedy, PE ;
Berger, EA ;
Pastan, I ;
Hamer, DH .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (37) :34383-34390
[38]   Decay characteristics of HIV-1-infected compartments during combination therapy [J].
Perelson, AS ;
Essunger, P ;
Cao, YZ ;
Vesanen, M ;
Hurley, A ;
Saksela, K ;
Markowitz, M ;
Ho, DD .
NATURE, 1997, 387 (6629) :188-191
[39]   Characterization of chemokine receptor utilization of viruses in the latent reservoir for human immunodeficiency virus type 1 [J].
Pierson, T ;
Hoffman, TL ;
Blankson, J ;
Finzi, D ;
Chadwick, K ;
Margolick, JB ;
Buck, C ;
Siliciano, JD ;
Doms, RW ;
Siliciano, RF .
JOURNAL OF VIROLOGY, 2000, 74 (17) :7824-7833
[40]   Reservoirs of human immunodeficiency virus type 1: The main obstacles to viral eradication [J].
Pomerantz, RJ .
CLINICAL INFECTIOUS DISEASES, 2002, 34 (01) :91-97